KLOW Blend 80mg (BPC-157, GHK-Cu, TB-500, KPV), Research Peptide Canada

Buy the KLOW blend in Canada from Anglo Peptides, a Canadian research-grade combination of BPC-157, GHK-Cu, TB-500 and KPV in a single vial. Every vial is produced in a cGMP-compliant facility, independently verified by third-party HPLC, and lyophilised for stability. Orders ship same-day in cold-pack packaging, arrive within 1 to 3 business days across Canada, and include a batch-specific certificate of analysis. The summary below reflects the published preclinical literature on the individual components and is provided for laboratory research context only.

What Is the KLOW Blend?

KLOW is a four-peptide research blend that combines 10 mg of BPC-157, 50 mg of GHK-Cu, 10 mg of TB-500 (thymosin beta-4 fragment) and 10 mg of KPV in one lyophilised vial, for 80 mg of total peptide content. It is effectively the three-peptide GLOW blend with the melanocortin-derived anti-inflammatory tripeptide KPV added, and is used in research settings examining tissue repair, dermal and connective-tissue pathways, and inflammatory signalling. Each component is individually characterised in the literature, and Anglo Peptides also offers them as standalone products.

Components and Their Mechanisms

BPC-157 (10 mg). A stable gastric pentadecapeptide that promotes angiogenesis through the VEGFR2 and nitric-oxide systems and supports soft-tissue healing in animal models.^[1][2]

GHK-Cu (50 mg). A naturally occurring copper-binding tripeptide that delivers bioavailable copper and stimulates collagen and extracellular-matrix synthesis in fibroblast and wound models.^[3]

TB-500 (10 mg). A synthetic fragment related to thymosin beta-4 that acts as an extracellular repair signal and has accelerated re-epithelialisation and angiogenesis in dermal wound models.^[4][5]

KPV (10 mg). The C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory activity through suppression of NF-κB signalling, without melanocortin-receptor pigmentation effects.^[6]

The research rationale for the four-way combination is that it pairs repair-oriented mechanisms, angiogenesis and cytoprotection (BPC-157), copper-dependent matrix synthesis (GHK-Cu) and actin-driven cell migration (TB-500), with the distinct anti-inflammatory action of KPV.

Research Applications

KLOW is studied in the context of tissue repair, skin and connective-tissue research, and inflammatory-signalling research, drawing on the individual evidence base of each peptide. All of that evidence is preclinical, from cell-culture and animal models, and none of the four components is an approved therapeutic. There are no human clinical trials of this specific four-peptide combination, and the blend is supplied for laboratory research use only.

Stability, Solubility and Handling

Anglo Peptides supplies KLOW as a single lyophilised powder containing all four peptides. For research it is reconstituted with sterile or bacteriostatic water. As GHK-Cu is a copper complex, avoid combining the reconstituted solution with strong chelators or high concentrations of reducing agents. Store the lyophilised powder cold, dark and desiccated, with long-term storage at -20°C; keep reconstituted solution refrigerated and use within a few weeks, avoiding repeated freeze-thaw cycles. These notes apply to in-vitro and animal research only.

Product Specifications

• Compound: KLOW blend (BPC-157 + GHK-Cu + TB-500 + KPV)
• Composition: BPC-157 10 mg, GHK-Cu 50 mg, TB-500 10 mg, KPV 10 mg
• Total peptide content: 80 mg per vial
• Purity: Components ≥99% by HPLC
• Form: Lyophilised powder
• Testing: Independent third-party HPLC and mass spectrometry
• Documentation: Batch-specific certificate of analysis
• Origin: Made in Canada

Quality, Testing and Canadian Sourcing

Every batch of the Anglo Peptides KLOW blend is independently tested with a lot-specific certificate of analysis. Producing and finishing vials in Canada lets us verify the full labelled content of each component and ship quickly without customs delays. Read more on our Canadian sourcing page. The individual components are available as BPC-157, GHK-Cu, TB-500 and KPV, and a three-peptide version without KPV is offered as the GLOW blend.

Why a Four-Peptide Blend

KLOW extends the three-peptide GLOW concept by adding KPV, and the rationale is to pair repair-oriented mechanisms with a distinct anti-inflammatory action in a single preparation. GHK-Cu contributes copper-dependent collagen and extracellular-matrix synthesis, TB-500 contributes actin regulation and cell migration, and BPC-157 contributes angiogenesis and cytoprotection, while KPV, the C-terminal tripeptide of alpha-MSH, contributes suppression of NF-kB-driven inflammatory signalling without melanocortin-receptor pigmentation effects. The research interest in combining all four is that tissue repair and inflammation are intertwined processes, so a preparation that touches both is convenient for protocols that examine them together. As with GLOW, this is a formulation and convenience decision rather than an independently validated intervention: there are no human clinical trials of this specific four-peptide blend, and the supporting evidence is the preclinical literature of each component. Researchers who need to isolate the contribution of any single peptide should use the standalone products.

Considerations for Research Use

The attribution caveat is even more pronounced with four active peptides than with three: an observed effect cannot be assigned to any one component without comparison against the peptides administered individually, so a sound study using KLOW will include single-peptide and vehicle controls. The fixed ratio in the vial constrains dose-response work unless the components are sourced separately, and the copper content of GHK-Cu carries the handling constraints noted above. Confirmation of identity and verification of purity for each component lot are essential, since an under-dosed, degraded or copper-depleted preparation will distort results. Every Anglo Peptides batch ships with third-party testing and a lot-specific certificate of analysis so the material matches the label.

Reconstitution, Storage and Handling in Detail

For laboratory use, the lyophilised powder is brought to room temperature before opening to avoid condensation, then reconstituted by adding sterile or bacteriostatic water slowly down the inside wall of the vial rather than directly onto the powder, and swirled gently rather than shaken. Because the blend contains the copper peptide GHK-Cu, avoid combining the reconstituted solution with strong chelators such as EDTA or high concentrations of reducing agents such as ascorbic acid, which can dissociate the copper and change what is being studied. Once reconstituted, keep the solution refrigerated at 2 to 8 degrees Celsius, protected from light, and use it within a defined window, aliquoting into single-use portions to avoid the repeated freeze-thaw cycles that degrade peptides. The lyophilised powder is more stable than solution and is best stored frozen, sealed and desiccated, for long-term holding. These are general research-handling conventions; the lot-specific certificate of analysis should always take precedence.

Frequently Asked Questions

References

1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PubMed
2. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. PubMed
3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PubMed
4. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PubMed
5. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PubMed
6. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PubMed

Research use only. The KLOW blend supplied by Anglo Peptides is intended exclusively for licensed laboratory and academic research. It is not a drug, dietary supplement, cosmetic, or medical product, and is not for human consumption, diagnosis, or treatment.

Researchers who buy KLOW blend from Anglo Peptides receive a vial verified to ≥99% purity, batch-tested by Janoshik Labs, and shipped from within Canada. Choose the 80mg size above.